AIM: To assess the impact of eukaryotic elongation factor 1 alpha 2 (eEF1A2) on hepatocellular carcinoma (HCC) cell proliferation, apoptosis, migration and invasion, and determine the underlying mechanisms. METHODS: eEF1A2 levels were detected in 62 HCC tissue samples and paired pericarcinomatous specimens, and the human HCC cell lines SK-HEP-1, HepG2 and BEF-7402, by real-time PCR and immunohistochemistry. Experimental groups included eEF1A2 silencing in BEL-7402 cells with lentivirus eEF1A2-shRNA (KD group) and eEF1A2 overexpression in SK-HEP-1 cells with eEF1A2 plasmid (OE group). Non-transfected cells (control group) and lentivirus-based empty vector transfected cells (NC group) were considered control groups. Cell proliferation (MTT and colony formation assays), apoptosis (Annexin V-APC assay), cell cycle (DNA ploidy assay), and migration and invasion (Transwell assays) were assessed. Protein levels of PI3K/Akt/NF-κB signaling effectors were evaluated by Western blot. RESULTS: eEF1A2 mRNA and protein levels were significantly higher in HCC cancer tissue samples than in paired pericarcinomatous and normal specimens. SK-HEP-1 cells showed lower eEF1A2 mRNA levels; HepG2 and BEL-7402 cells showed higher eEF1A2 mRNA levels, with BEL-7402 cells displaying the highest amount. Efficient eEF1A2 silencing resulted in reduced cell proliferation, migration and invasion, increased apoptosis, and induced cell cycle arrest. The PI3K/Akt/NF-κB signaling pathway was notably inhibited. Inversely, eEF1A2 overexpression resulted in promoted cell proliferation, migration and invasion. CONCLUSION: eEF1A2, highly expressed in HCC, is a potential oncogene. Its silencing significantly decreases HCC tumorigenesis, likely by inhibiting PI3K/Akt/NF-κB signaling.
AIM: To assess the impact of eukaryotic elongation factor 1 alpha 2 (eEF1A2) on hepatocellular carcinoma (HCC) cell proliferation, apoptosis, migration and invasion, and determine the underlying mechanisms. METHODS:eEF1A2 levels were detected in 62 HCC tissue samples and paired pericarcinomatous specimens, and the human HCC cell lines SK-HEP-1, HepG2 and BEF-7402, by real-time PCR and immunohistochemistry. Experimental groups included eEF1A2 silencing in BEL-7402 cells with lentivirus eEF1A2-shRNA (KD group) and eEF1A2 overexpression in SK-HEP-1 cells with eEF1A2 plasmid (OE group). Non-transfected cells (control group) and lentivirus-based empty vector transfected cells (NC group) were considered control groups. Cell proliferation (MTT and colony formation assays), apoptosis (Annexin V-APC assay), cell cycle (DNA ploidy assay), and migration and invasion (Transwell assays) were assessed. Protein levels of PI3K/Akt/NF-κB signaling effectors were evaluated by Western blot. RESULTS:eEF1A2 mRNA and protein levels were significantly higher in HCC cancer tissue samples than in paired pericarcinomatous and normal specimens. SK-HEP-1 cells showed lower eEF1A2 mRNA levels; HepG2 and BEL-7402 cells showed higher eEF1A2 mRNA levels, with BEL-7402 cells displaying the highest amount. Efficient eEF1A2 silencing resulted in reduced cell proliferation, migration and invasion, increased apoptosis, and induced cell cycle arrest. The PI3K/Akt/NF-κB signaling pathway was notably inhibited. Inversely, eEF1A2 overexpression resulted in promoted cell proliferation, migration and invasion. CONCLUSION:eEF1A2, highly expressed in HCC, is a potential oncogene. Its silencing significantly decreases HCC tumorigenesis, likely by inhibiting PI3K/Akt/NF-κB signaling.
Authors: Rossella Pellegrino; Diego F Calvisi; Olaf Neumann; Venkatesh Kolluru; Josephine Wesely; Xin Chen; Chunmei Wang; Torsten Wuestefeld; Sara Ladu; Nahla Elgohary; Justo Lorenzo Bermejo; Bernhard Radlwimmer; Martin Zörnig; Lars Zender; Frank Dombrowski; Matthias Evert; Peter Schirmacher; Thomas Longerich Journal: Hepatology Date: 2014-03-27 Impact factor: 17.425
Authors: Nisha Anand; Sabita Murthy; Gudrun Amann; Meredith Wernick; Lisa A Porter; I Howard Cukier; Colin Collins; Joe W Gray; Joachim Diebold; Doug J Demetrick; Jonathan M Lee Journal: Nat Genet Date: 2002-06-10 Impact factor: 38.330
Authors: Valentine B Andela; Andrew H Gordon; George Zotalis; Randy N Rosier; Jeffrey J Goater; Gregory D Lewis; Edward M Schwarz; J Edward Puzas; Regis J O'Keefe Journal: Clin Orthop Relat Res Date: 2003-10 Impact factor: 4.176
Authors: Miriam Martini; Maria Chiara De Santis; Laura Braccini; Federico Gulluni; Emilio Hirsch Journal: Ann Med Date: 2014-06-05 Impact factor: 4.709
Authors: B Scaggiante; B Dapas; S Bonin; M Grassi; C Zennaro; R Farra; L Cristiano; S Siracusano; F Zanconati; C Giansante; G Grassi Journal: Br J Cancer Date: 2011-11-17 Impact factor: 7.640